Ursodeoxycholic acid in the treatment of primary biliary cirrhosis: A short‐term, randomized, double‐blind controlled, cross‐over study with long‐term follow up

Journal of Gastroenterology and Hepatology

Volumn 8, Issue 3, 1993, Pages 217-223

  HWANG, S J ^a   CHAN, C Y ^a   LEE, S D ^a   WU, J C ^a   TSAY, S H ^b   LO, K J ^a  

^a Division of Gastroenterology   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Mayo risk score; primary biliary cirrhosis; ursodeoxycholic acid

Indexed keywords

URSODEOXYCHOLIC ACID;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PRIMARY BILIARY CIRRHOSIS; RISK; TAIWAN;

ALKALINE PHOSPHATASE; BILIRUBIN; CHOLESTEROL; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; GAMMA-GLUTAMYLTRANSFERASE; HUMAN; LIVER CIRRHOSIS, BILIARY; MALE; MIDDLE AGE; SERUM ALBUMIN; SUPPORT, NON-U.S. GOV'T; URSODEOXYCHOLIC ACID;

EID: 0027286162     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.1993.tb01189.x     Document Type: Article

References (38)

1. Primary biliary cirrhosis
2. Primary biliary cirrhosis: a model autoimmune disease
3. Ultrastructural immunocytochemical analysis of lymphocytes infiltrating bile duct epithelium in primary biliary cirrhosis
4. Asymtomatic primary biliary cirrhosis—long term follow‐up and natural history
5. Serum bilirubin: a prognostic factor in primary biliary cirrhosis
6. A prospective trial of d‐penicillamine in primary biliary cirrhosis
7. Double blind controlled trial of d‐penicillamine in patients with primary biliary cirrhosis
8. Beneficial effect of azathioprine and prediction of prognosis in primary biliary cirrhosis: final results of an international trial
9. Randomized trial of chlorambucil for primary biliary cirrhosis
10. A pilot, double‐blind controlled 1‐year trial of prednisolone treatment in primary biliary cirrhosis: hepatic improvement but greater bone loss
11. Clinical and statistical analyses of new and evolving therapies for primary biliary cirrhosis
12. Pilot study of cyclosporin A in patients with symptomatic primary biliary cirrhosis
13. A controlled trial of cyclosporin in the treatment of primary biliary cirrhosis
14. A prospective trial of colchicine for primary biliary cirrhosis
15. Evaluation of colchicine therapy in primary biliary cirrhosis
16. Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis
17. Primary biliary cirrhosis in Taiwan
18. Prognosis in primary biliary cirrhosis: Model for Decision making
19. Influence of hydroxylation and conjugation of bile salts on their membrane damaging properties: studies on isolated hepatocytes and membrane vesicles
20. Tauroursodeoxycholate prevents biliary protein excretion induced by other bile salts
21. Effect of ursodeoxycholate on bile flow in the rat
22. The ursodeoxycholate dose‐dependent formation of ursodeoxycholate‐glucuronide in the rat and the choleretic potencies
23. Effect of ursodeoxycholic acid on bile acid metabolism in primary biliary cirrhosis
24. Ursodeoxycholate reduces hepatotoxicity of bile salts in primary human hepatocyte
25. Hepatic expression of class I and class II major histocompatibility complex molecules in primary biliary cirrhosis: effect of ursodeoxycholic acid
26. Hepatocellular and biliary expression of HLA antigen in primary biliary cirrhosis before and after ursodeoxycholic acid therapy
27. A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis
28. A multi‐center double‐blind controlled trial of ursodeoxycholic acid for primary biliary cirrhosis
29. Ursodeoxycholic acid in primary biliary cirrhosis: results of a controlled double‐blind trial
30. Improvement of biliary enzyme levels and itching as a result of long‐term administration of ursodeoxycholic acid in primary biliary cirrhosis
31. Immunomodulatory effects of ursodeoxycholic acid on immune responses
32. Therapeutic effect of ursodeoxycholic acid on early stage primary biliary cirrhosis
33. Ursodeoxycholic acid in primary biliary cirrhosis: no evidence for toxicity in the stages I to III
34. Progression of primary biliary cirrhosis with ursodeoxycholic acid therapy
35. Prediction of survival of patients with primary biliary cirrhosis: examination of the Mayo clinic model on a group of patients with known endpoint
36. No symptomatic or histological benefit from ursodeoxycholic acid treatment in PBC after 1 year controlled pilot study